169 related articles for article (PubMed ID: 28071612)
1. Expression of Raf kinase inhibitor protein in human hepatoma tissues by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight methods.
Tsao DA; Shiau YF; Tseng CS; Chang HR
Indian J Cancer; 2016; 53(2):216-219. PubMed ID: 28071612
[TBL] [Abstract][Full Text] [Related]
2. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells.
Lee HC; Tian B; Sedivy JM; Wands JR; Kim M
Gastroenterology; 2006 Oct; 131(4):1208-17. PubMed ID: 17030190
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Raf kinase inhibitor protein and its significance in invasion and metastasis of hepatocellular carcinoma].
Wu XH; Wang SX; Yang YJ; Li JK; Xu Z; Tang RF
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):358-62. PubMed ID: 21875465
[TBL] [Abstract][Full Text] [Related]
4. Raf kinase inhibitor protein mediated signaling inhibits invasion and metastasis of hepatocellular carcinoma.
Wu X; Yang Y; Xu Z; Li J; Yang B; Feng N; Zhang Y; Wang S
Biochim Biophys Acta; 2016 Feb; 1860(2):384-91. PubMed ID: 26116914
[TBL] [Abstract][Full Text] [Related]
5. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma.
Schuierer MM; Bataille F; Weiss TS; Hellerbrand C; Bosserhoff AK
Oncol Rep; 2006 Sep; 16(3):451-6. PubMed ID: 16865242
[TBL] [Abstract][Full Text] [Related]
6. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.
Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP
J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951
[TBL] [Abstract][Full Text] [Related]
7. Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma.
Poma P; Labbozzetta M; Vivona N; Porcasi R; D'Alessandro N; Notarbartolo M
OMICS; 2012 Nov; 16(11):579-88. PubMed ID: 23095110
[TBL] [Abstract][Full Text] [Related]
8. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins.
Kim J; Kim SH; Lee SU; Ha GH; Kang DG; Ha NY; Ahn JS; Cho HY; Kang SJ; Lee YJ; Hong SC; Ha WS; Bae JM; Lee CW; Kim JW
Electrophoresis; 2002 Dec; 23(24):4142-56. PubMed ID: 12481271
[TBL] [Abstract][Full Text] [Related]
9. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.
Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F
Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933
[TBL] [Abstract][Full Text] [Related]
10. Serum and tissue proteomic signatures of patients with hepatocellular carcinoma using 2‑D gel electrophoresis.
Peng H; Yan Z; Zeng X; Zhang S; Jiang H; Huang H; Zhuo H
Mol Med Rep; 2019 Aug; 20(2):1025-1038. PubMed ID: 31173207
[TBL] [Abstract][Full Text] [Related]
11. Differential proteomic analysis of hepatocellular carcinoma.
Corona G; De Lorenzo E; Elia C; Simula MP; Avellini C; Baccarani U; Lupo F; Tiribelli C; Colombatti A; Toffoli G
Int J Oncol; 2010 Jan; 36(1):93-9. PubMed ID: 19956837
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.
Li N; Long Y; Fan X; Liu H; Li C; Chen L; Wang Z
J Exp Clin Cancer Res; 2009 Aug; 28(1):122. PubMed ID: 19715608
[TBL] [Abstract][Full Text] [Related]
13. A proteomic approach in investigating the hepatoprotective mechanism of Schisandrin B: role of raf kinase inhibitor protein.
Chen Y; Ip SP; Ko KM; Poon TC; Ng EW; Lai PB; Mao QQ; Xian YF; Che CT
J Proteome Res; 2011 Jan; 10(1):299-304. PubMed ID: 21155602
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
[TBL] [Abstract][Full Text] [Related]
15. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma.
Notarbartolo M; Giannitrapani L; Vivona N; Poma P; Labbozzetta M; Florena AM; Porcasi R; Muggeo VM; Sandonato L; Cervello M; Montalto G; D'Alessandro N
OMICS; 2011 May; 15(5):267-72. PubMed ID: 21332389
[TBL] [Abstract][Full Text] [Related]
16. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
17. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies.
Ritorto MS; Borlak J
J Proteome Res; 2011 Jul; 10(7):3012-30. PubMed ID: 21644509
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the Golgi proteome of hepatocellular carcinoma with that of the adjacent non-tumor tissues].
Xiao Z; Yi YF; He TT; Li YQ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):23-6. PubMed ID: 20128964
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma.
Park KS; Kim H; Kim NG; Cho SY; Choi KH; Seong JK; Paik YK
Hepatology; 2002 Jun; 35(6):1459-66. PubMed ID: 12029631
[TBL] [Abstract][Full Text] [Related]
20. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.
Qiao B; Wang J; Xie J; Niu Y; Ye S; Wan Q; Ye Q
Int J Mol Med; 2012 May; 29(5):832-40. PubMed ID: 22344546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
